ALFA Filings
Every announcement, straight from the exchange
Every Alkem Laboratories merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.
Alkem Laboratories completed the acquisition of a 51-55% stake in Swiss firm Occlutech Holding AG. Occlutech now becomes a step-down subsidiary of the company.
Alkem Laboratories acquired equity shares worth Rs. 1,100 Crore in its subsidiary, Alkem Medtech, via a rights issue. The investment supports Medtech's cardiovascular and orthopedic business.
Alkem Medtech will acquire 51-55% of Occlutech Holding AG through a supplementary Share Purchase Agreement. This acquisition expands Alkem's international footprint.
Alkem Laboratories Limited incorporated a new wholly-owned subsidiary, Alkem Pharma Trading FZCO, in the UAE on March 27, 2026. The new entity will focus on exporting pharmaceutical products to African, South East Asian, and non-UAE markets. This strategic move aims to expand the company's international footprint and export capabilities.
Alkem Laboratories Limited incorporated a wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE, on March 27, 2026. The ₹9.18 Crore investment aims to facilitate pharmaceutical exports to African, South East Asian, and non-UAE markets. This strategic move strengthens Alkem's international presence and export capabilities.